A statement released earlier today by Barclays PLC about Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) bumps down the target price to $50.00
- Updated: October 8, 2016
Just yesterday Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) traded -5.36% lower at $70.30. Alnylam Pharmaceuticals, Inc.’s 50-day moving average is $70.69 and its 200-day moving average is $66.05. The last closing price is up -48.12% from the 200-day moving average, compared to the Standard & Poor's 500 Index which has decreased -0.01% over the same time period. 5,197,185 shares of ALNY traded hands, up from an average trading volume of 981,972
Stating a potential downside of -0.29%, Barclays PLC dropped the price target of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) to $50.00
Previously on Thursday September 29, 2016, Janney Capital reported on Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) increased the target price from $0.00 to $74.00. At the time, this indicated a possible downside of -0.03%.
Recent Performance Chart
Alnylam Pharmaceuticals, Inc. has 52 week low of $33.16 and a 52 week high of $110.75 and has a market capitalization of $0.
In addition to Barclays PLC reporting its stock price target, a total of 11 brokers have issued a research note on the company. The average stock price target is $117.09 with 3 brokers rating the stock a strong buy, 8 brokers rating the stock a buy, 2 brokers rating the stock a hold, 0 brokers rating the stock a underperform, and finally 0 brokers rating the stock a sell.
Brief Synopsis On Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)
Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is engaged in developing therapeutics based on ribonucleic acid (RNA) interference (RNAi). It is focused on the use of its N-acetylgalactosamine (GalNAc)-conjugate strategy for delivery of small interfering RNAs (siRNAs). Its pipeline of investigational RNAi therapeutics focuses in three Strategic Therapeutic Areas (STArs): Genetic Medicines; Cardio-Metabolic Disease, and Hepatic Infectious Disease. Its Genetic medicines include Patisiran (ALN-TTR02), Revusiran (ALN-TTRsc), Fitusiran (ALN-AT3), ALN-CC5, ALN-AS1, and additional genetic programs, including ALN-AAT, ALN-GO1 and ALN-TMP. Products for Cardio-Metabolic Disease STAr include ALN-PCSsc and other cardio-metabolic disease programs ALN-AC3 and ALN-ANG targeting Angiopoetin-like 3 (ANGPTL3). Products for Hepatic Infectious Disease STAr include ALN-HBV, ALN-HDV and ALN-PDL. It also owns Enhanced Stabilization Chemistry, GalNAc-conjugate delivery platform.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.